Journal: Proceedings of the Japan Academy. Series B, Physical and Biological Sciences

Article Title: Ivermectin, 'Wonder drug' from Japan: the human use perspective

doi: 10.2183/pjab.87.13

Figure Lengend Snippet: Effect of ivermectin and diethylcarbamazine (DEC) on microfilariae in the skin.

Article Snippet: With respect to the use of ivermectin for Lymphatic filariasis, again Merck took the initial lead, with TDR being involved in organising, expanding and broadening the research and clinical trials.

Techniques:

Journal: Proceedings of the Japan Academy. Series B, Physical and Biological Sciences

Article Title: Ivermectin, 'Wonder drug' from Japan: the human use perspective

doi: 10.2183/pjab.87.13

Figure Lengend Snippet: Trend in ivermectin treatments approved (1988–2008).

Article Snippet: With respect to the use of ivermectin for Lymphatic filariasis, again Merck took the initial lead, with TDR being involved in organising, expanding and broadening the research and clinical trials.

Techniques:

Journal: Proceedings of the Japan Academy. Series B, Physical and Biological Sciences

Article Title: Ivermectin, 'Wonder drug' from Japan: the human use perspective

doi: 10.2183/pjab.87.13

Figure Lengend Snippet: Molecular diagrams of avermectin and the di-hydro derivative, ivermectin.

Article Snippet: With respect to the use of ivermectin for Lymphatic filariasis, again Merck took the initial lead, with TDR being involved in organising, expanding and broadening the research and clinical trials.

Techniques:

Journal: Proceedings of the Japan Academy. Series B, Physical and Biological Sciences

Article Title: Ivermectin, 'Wonder drug' from Japan: the human use perspective

doi: 10.2183/pjab.87.13

Figure Lengend Snippet: Effect of ivermectin and diethylcarbamazine (DEC) on microfilariae in the Anterior Chamber of the eye.

Article Snippet: With respect to the use of ivermectin for Lymphatic filariasis, again Merck took the initial lead, with TDR being involved in organising, expanding and broadening the research and clinical trials.

Techniques:

Journal: PLoS Neglected Tropical Diseases

Article Title: The Galabat-Metema cross-border onchocerciasis focus: The first coordinated interruption of onchocerciasis transmission in Africa

doi: 10.1371/journal.pntd.0007830

Figure Lengend Snippet: Treatment Coverage of the eligible population of ivermectin MDA provided once or twice yearly in Galabat subfocus and The Metema subfocus (Metema and West Armachiho districts), by year (2003–2017). Not copyrighted, and was created in Ms Excel.

Article Snippet: In sub-Saharan Africa, mass drug administration (MDA) of the medicine ivermectin (Mectizan, donated by Merck & Co) kills microfilariae, thus reducing skin and eye disease and impeding transmission of the infection.

Techniques: Multiple Displacement Amplification

Journal: PLoS Neglected Tropical Diseases

Article Title: The Galabat-Metema cross-border onchocerciasis focus: The first coordinated interruption of onchocerciasis transmission in Africa

doi: 10.1371/journal.pntd.0007830

Figure Lengend Snippet: Number of MDA ivermectin treatments provided once or twice yearly in Galabat sub-focus (Sudan) and Metema sub-focus in Metema and West Armachiho districts of Ethiopia) - 2003–2017. Not copyrighted, and was created in Ms Excel.

Article Snippet: In sub-Saharan Africa, mass drug administration (MDA) of the medicine ivermectin (Mectizan, donated by Merck & Co) kills microfilariae, thus reducing skin and eye disease and impeding transmission of the infection.

Techniques: Multiple Displacement Amplification

Journal: bioRxiv

Article Title: Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin and chloroquine in Rhesus Macaques

doi: 10.1101/2020.04.27.065409

Figure Lengend Snippet: Pharmacokinetic simulation of ivermectin concentration-time profile when given as 0.3, 0.6 and 1.2 mg/kg for 7 days in Rhesus macaques

Article Snippet: Ivermectin compound (Lot # MKBZ1802V, Sigma Aldrich, St. Louis, MO, USA) was dissolved in 100% DMSO and used at a final concentration of 100 µg/ml in an 8-point, 2-fold serial dilution.

Techniques: Concentration Assay

Journal: bioRxiv

Article Title: Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin and chloroquine in Rhesus Macaques

doi: 10.1101/2020.04.27.065409

Figure Lengend Snippet: Mean plasma concentration-time profiles of ivermectin 24 hours after the first and seventh dose when administered ivermectin at 0.3, 0.6, and 1.2 mg/kg with and without chloroquine (10 mg/kg)

Article Snippet: Ivermectin compound (Lot # MKBZ1802V, Sigma Aldrich, St. Louis, MO, USA) was dissolved in 100% DMSO and used at a final concentration of 100 µg/ml in an 8-point, 2-fold serial dilution.

Techniques: Concentration Assay

Journal: bioRxiv

Article Title: Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin and chloroquine in Rhesus Macaques

doi: 10.1101/2020.04.27.065409

Figure Lengend Snippet: Relative ivermectin parameter values for C max (left panel) and AUC 24 hr (right panel)

Article Snippet: Ivermectin compound (Lot # MKBZ1802V, Sigma Aldrich, St. Louis, MO, USA) was dissolved in 100% DMSO and used at a final concentration of 100 µg/ml in an 8-point, 2-fold serial dilution.

Techniques:

Journal: bioRxiv

Article Title: Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin and chloroquine in Rhesus Macaques

doi: 10.1101/2020.04.27.065409

Figure Lengend Snippet: Ivermectin concentrations achieved in macaques 24 hours post first oral dose

Article Snippet: Ivermectin compound (Lot # MKBZ1802V, Sigma Aldrich, St. Louis, MO, USA) was dissolved in 100% DMSO and used at a final concentration of 100 µg/ml in an 8-point, 2-fold serial dilution.

Techniques:

Journal: bioRxiv

Article Title: Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin and chloroquine in Rhesus Macaques

doi: 10.1101/2020.04.27.065409

Figure Lengend Snippet: In vitro Plasmodium cynomolgi liver-stage ivermectin inhibition prophylactic results. Prophylactic (days 1-3) exposure of P. cynomolgi to ivermectin demonstrated marginal inhibition of liver schizonts (IC 50 = 9.12 μg/ml) and hypnozoites (IC 50 = 25.59 μg/ml). LS = liver-stage. Graph bars represent means with standard deviation of biological replicates (n = 3) with experimental replicates (n = 2).

Article Snippet: Ivermectin compound (Lot # MKBZ1802V, Sigma Aldrich, St. Louis, MO, USA) was dissolved in 100% DMSO and used at a final concentration of 100 µg/ml in an 8-point, 2-fold serial dilution.

Techniques: In Vitro, Inhibition, Standard Deviation

Journal: ACS Omega

Article Title: Ivermectin Promotes Peripheral Nerve Regeneration during Wound Healing

doi: 10.1021/acsomega.8b01451

Figure Lengend Snippet: Treatment of dermal fibroblasts with increasing concentrations of ivermectin results in the upregulation of GFAP as well as the development of an elongated morphology reminiscent of Schwann cells. (a) Dermal fibroblasts were treated with varying concentrations of ivermectin for 4 and 8 days, then subjected to qRT-PCR analysis of GFAP expression. (b) GFAP immunostaining demonstrates that dermal fibroblasts treated with relatively higher concentrations of ivermectin for 8 days results in an increase of GFAP expression as well as a change in morphology, which resembles a Schwann cell-like phenotype, scale bar: 100 μM. *** P ≤ 0.001; as determined by one-way ANOVA with post-hoc Tukey test. Error bars show mean ± SD.

Article Snippet: Human dermal fibroblasts (hDFs) and hiNSCs were treated with 1 μM ivermectin or 1 μM DMSO (control) for 6 h. hiNSCs were dissociated and labeled with lipophilic fluorescent dye DiD (Invitrogen) according to manufacturer’s protocol to monitor their growth in the collagen gels.

Techniques: Quantitative RT-PCR, Expressing, Immunostaining

Journal: ACS Omega

Article Title: Ivermectin Promotes Peripheral Nerve Regeneration during Wound Healing

doi: 10.1021/acsomega.8b01451

Figure Lengend Snippet: Ivermectin promotes wound healing of dermal biopsies in vivo. (a) Schematic diagram of experimental design. Biopsies (2 × 8 mm 2 ) were taken from the dorsal dermal layer of each mouse. In the right side wound, 30 μL collagen gels containing 10 μM ivermectin or DMSO (control) were pipetted onto the wound and allowed to solidify. The left side wounds remained untreated, and served as additional controls. Both wounds were sealed using Tegaderm, and wound progression was followed over the course of 12 days. (b) Images of gross morphology of wound healing over time. (c) Quantification of wound size over time. * P ≤ 0.05, ** P ≤ 0.01; as determined by two-tailed t -test. Error bars show mean ± SD.

Article Snippet: Human dermal fibroblasts (hDFs) and hiNSCs were treated with 1 μM ivermectin or 1 μM DMSO (control) for 6 h. hiNSCs were dissociated and labeled with lipophilic fluorescent dye DiD (Invitrogen) according to manufacturer’s protocol to monitor their growth in the collagen gels.

Techniques: In Vivo, Two Tailed Test

Journal: ACS Omega

Article Title: Ivermectin Promotes Peripheral Nerve Regeneration during Wound Healing

doi: 10.1021/acsomega.8b01451

Figure Lengend Snippet: Treatment of dermal fibroblasts with ivermectin induces migration of differentiated neurons. (a) Schematic diagram of experimental design. Human dermal fibroblasts were seeded into the bottom of cell culture plates, subsequently treated with or without ivermectin, and washed repeatedly to remove the drug. Differentiated DiD-labeled neurons were seeded onto coated transwells (8 μM pore size), which were placed into the wells containing fibroblasts. Cells were cultured in low serum media (to minimize potential cell proliferation) overnight, and the relative number of cells migrating to the bottom of transwells was quantified. (b) Images of fluorescently labeled neurons that migrated to the bottom of transwells upon co-culture with dermal fibroblasts pretreated with or without ivermectin, scale bar: 200 μM. (c) Quantification of migrated cells. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; as determined by two-tailed t -test. Error bars show mean ± SD.

Article Snippet: Human dermal fibroblasts (hDFs) and hiNSCs were treated with 1 μM ivermectin or 1 μM DMSO (control) for 6 h. hiNSCs were dissociated and labeled with lipophilic fluorescent dye DiD (Invitrogen) according to manufacturer’s protocol to monitor their growth in the collagen gels.

Techniques: Migration, Cell Culture, Labeling, Co-Culture Assay, Two Tailed Test

Journal: ACS Omega

Article Title: Ivermectin Promotes Peripheral Nerve Regeneration during Wound Healing

doi: 10.1021/acsomega.8b01451

Figure Lengend Snippet: Treatment with ivermectin causes dermal fibroblasts to uptake extracellular glutamate and to express glial cell line-derived neurotrophic growth factor (GDNF). (a) Dermal fibroblasts were treated with various concentrations of ivermectin overnight, and cell culture media was assayed to determine extracellular glutamate concentration. (b) Dermal fibroblasts were treated with or without 1 μM ivermectin for 4 days, then subjected to quantitative real-time polymerase chain reaction (qRT-PCR) analysis for various neurotrophic growth factors. (c) Immunostaining results of dermal fibroblasts treated with ivermectin show an increase in GDNF expression with increasing ivermectin concentration, scale bar: 100 μM. (d) Enzyme-linked immunosorbent assay (ELISA) of cell culture media harvested from dermal fibroblasts treated with ivermectin for 4 days indicates that GDNF is secreted from ivermectin-treated fibroblasts. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; as determined by one-way ANOVA with post-hoc Tukey test. Error bars show mean ± SD.

Article Snippet: Human dermal fibroblasts (hDFs) and hiNSCs were treated with 1 μM ivermectin or 1 μM DMSO (control) for 6 h. hiNSCs were dissociated and labeled with lipophilic fluorescent dye DiD (Invitrogen) according to manufacturer’s protocol to monitor their growth in the collagen gels.

Techniques: Derivative Assay, Cell Culture, Concentration Assay, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Immunostaining, Expressing, Enzyme-linked Immunosorbent Assay

Journal: ACS Omega

Article Title: Ivermectin Promotes Peripheral Nerve Regeneration during Wound Healing

doi: 10.1021/acsomega.8b01451

Figure Lengend Snippet: Treatment of dermal fibroblasts with ivermectin induces proliferation in adjacent neural stem cells in 3D co-cultures. (a) Schematic diagram of experimental design. Human dermal fibroblasts (hDFs) and human induced neural stem cells (hiNSCs) fluorescently labeled with DiD dye were separately treated with or without 1 μM ivermectin (as indicated by “+” or “–”, respectively) and subsequently washed repeatedly to remove the drug, seeded into 3D bilayer collagen gel constructs, and cultured for 5 days. (b) Low-magnification view of 3D collagen gel constructs, scale bar: 500 μM. (c) Cryosections of collagen gels immunostained for proliferation marker, Ki67, scale bar: 100 μM. (d) Quantification of Ki67-positive DiD-labeled neural stem cells. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; as determined by one-way analysis of variance (ANOVA) with post-hoc Tukey test. Error bars show mean ± SD.

Article Snippet: Human dermal fibroblasts (hDFs) and hiNSCs were treated with 1 μM ivermectin or 1 μM DMSO (control) for 6 h. hiNSCs were dissociated and labeled with lipophilic fluorescent dye DiD (Invitrogen) according to manufacturer’s protocol to monitor their growth in the collagen gels.

Techniques: Labeling, Construct, Cell Culture, Marker

Journal: ACS Omega

Article Title: Ivermectin Promotes Peripheral Nerve Regeneration during Wound Healing

doi: 10.1021/acsomega.8b01451

Figure Lengend Snippet: Ivermectin facilitates wound healing by inducing the differentiation of glia-like cells that promote nerve growth. Cryosections of the wound sites were immunostained and quantified to assay for the presence of (a) glial-derived growth factor (GDNF), (b) glial fibrillary acidic protein (GFAP), and (c) peripheral nerve marker (PGP9.5), scale bar: 100 μM. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; as determined by two-tailed t -test. Error bars show mean ± SD.

Article Snippet: Human dermal fibroblasts (hDFs) and hiNSCs were treated with 1 μM ivermectin or 1 μM DMSO (control) for 6 h. hiNSCs were dissociated and labeled with lipophilic fluorescent dye DiD (Invitrogen) according to manufacturer’s protocol to monitor their growth in the collagen gels.

Techniques: Derivative Assay, Marker, Two Tailed Test

Journal: Filaria Journal

Article Title: Repeated high doses of avermectins cause prolonged sterilisation, but do not kill, Onchocerca ochengi adult worms in African cattle

doi: 10.1186/1475-2883-4-8

Figure Lengend Snippet: Mean number (× 1000) of embryonic stages 'o' (small and large morulae, horseshoe and pretzel stages) and intra-uterine mf of O. ochengi per nodule, over-laid with the number of pathological stages '■ 'calculated from the median percent of pathological forms before and up to 24 months following treatment with ivermectin or doramectin.

Article Snippet: Three groups of 3 cows were either treated at monthly intervals (7 treatments) with ivermectin (Ivomec® , Merck and Co. Inc.) at 500 μg/kg or doramectin (Dectamax® , Pfizer) at 500 μg/kg or not treated as controls.

Techniques:

Journal: Filaria Journal

Article Title: Repeated high doses of avermectins cause prolonged sterilisation, but do not kill, Onchocerca ochengi adult worms in African cattle

doi: 10.1186/1475-2883-4-8

Figure Lengend Snippet: Mean (with standard deviation) OD 492 of female (a) and male (b) O. ochengi formazan formation after MTT reduction before and up to 24 months after treatment (from 18 months after the start of treament OD 492 is standardised for 10 mm of length). ■ = control, □ = ivermectin, = doramectin. (N.B. The mean OD 492 reading for males was first calculated for each nodule and this was then used to calculate the group means given in Figure 1b) Foot notes. (a) Two-way ANOVA for effect of timepoint and treatment group: Interaction effect between group and timepoint p = 0.44; group effect p = 0.62; effect of timepoint p = 0.02. (b) Two-way ANOVA for effect of timepoint and treatment group: Interaction effect between group and timepoint p = 0.69; group effect p = 0.79; effect of timepoint p = 0.02.

Article Snippet: Three groups of 3 cows were either treated at monthly intervals (7 treatments) with ivermectin (Ivomec® , Merck and Co. Inc.) at 500 μg/kg or doramectin (Dectamax® , Pfizer) at 500 μg/kg or not treated as controls.

Techniques: Standard Deviation, MTT Assay

Journal: PLoS Neglected Tropical Diseases

Article Title: Scabies-infested pregnant women: A critical therapeutic challenge

doi: 10.1371/journal.pntd.0008929

Figure Lengend Snippet: Hand of a scabies-infested pregnant woman with diffuse damaged skin. A 38-year-old Tunisian woman at 16 weeks of pregnancy presenting scabies as did her husband and their 2 children. Scabies was present for 4 months, and the skin was largely damaged with widespread eczematous on the limbs, trunk, breast, and nipples. Therapeutic management was challenging because topical scabicides were inconceivable, and oral ivermectin was unavailable in Tunisia. Oral ivermectin, 200 μg/kg body weight, repeated 1 week apart and brought back from the European market by the dermatologist, finally allowed for effective and safe treatment without any adverse pregnancy outcome. Collection of Prof . Mourad Mokni (MD , PhD) , Department of Dermatology , La Rabta Hospital , Tunis , Tunisia .

Article Snippet: These basic precautions mainly rely on experimental studies in mice showing adverse pregnancy outcomes (oral clefts and clubbed forepaws) at doses 10 to 100 times higher than current ivermectin human doses (150 to 200 μg/kg) ( https://www.merck.ca).

Techniques:

Journal: PLoS Neglected Tropical Diseases

Article Title: A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection

doi: 10.1371/journal.pntd.0002953

Figure Lengend Snippet: Percentage reduction from pre-treatment in skin microfilariae density (mean, standard deviation) 8 days, 1, 2, 3, 6, 12 and 18 months after treatment by treatment group. A Total e-mITT population, B Severely infected in the e-mITT population treated with ivermectin or 8 mg moxidectin. For the ivermectin treatment group, means and standard deviations are shown across all severely infected and without the suboptimal microfilariae responders (Ivermectin - SOMR). Tx – treatment, SD – standard deviation shown in one direction. Marker positions for different treatment groups have been placed around the measurement time point to allow, to the extent possible, differentiation between overlapping means and SD.

Article Snippet: Interventions, randomized treatment allocation, blinding and treatment The 3 mg ivermectin tablets (purchased from Merck and Co. Inc), 2 mg moxidectin tablets developed for human use, as well as placebo were provided by Wyeth in identical looking capsules.

Techniques: Standard Deviation, Infection, Marker

Journal: PLoS Neglected Tropical Diseases

Article Title: A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection

doi: 10.1371/journal.pntd.0002953

Figure Lengend Snippet: Number of participants by cohort screened, randomized, treated and analyzed. 1. Cohorts were screened for and eligible participants randomized and treated in sequential order. 2. In each dose group, subjects were randomized 3∶1 to the dose of moxidectin (Moxi) specified and ivermectin (IVM). 3. Mild:

Article Snippet: Interventions, randomized treatment allocation, blinding and treatment The 3 mg ivermectin tablets (purchased from Merck and Co. Inc), 2 mg moxidectin tablets developed for human use, as well as placebo were provided by Wyeth in identical looking capsules.

Techniques:

Journal: PLoS Neglected Tropical Diseases

Article Title: A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection

doi: 10.1371/journal.pntd.0002953

Figure Lengend Snippet: Skin microfilariae density in individual participants pre-treatment (0) and at the different times post-treatment (e-mITT population) in the four treatment groups. A Ivermectin. The data for the three participants treated with ivermectin whose decrease in skin microfilariae levels did not meet the criteria of ‘adequate response’ are indicated by markers at the evaluation time points. B 2 mg moxidectin, C 4 mg moxidectin, D 8 mg moxidectin.

Article Snippet: Interventions, randomized treatment allocation, blinding and treatment The 3 mg ivermectin tablets (purchased from Merck and Co. Inc), 2 mg moxidectin tablets developed for human use, as well as placebo were provided by Wyeth in identical looking capsules.

Techniques:

Journal: PLoS Neglected Tropical Diseases

Article Title: A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection

doi: 10.1371/journal.pntd.0002953

Figure Lengend Snippet: Number of live female macrofilaria, live young female macrofilaria and live male macrofilaria in excised nodules vs skin mf density 18 months after treatment by treatment. A. Ivermectin, B. 2×axis maximum was set to 7. The data for one participant treated with 2 mg moxidectin who had 13 live female macrofilaria and a skin mf density of 8.2 mf/mg are thus not displayed. Participants with 0 macrofilaria in excised nodules either had no palpable nodules or all excised nodules were non-onchocercal based on histological evaluation. Abbreviations: LI FM – live female macrofilariae, Y FM – live young female macrofilariae, LI MW – live male macrofilariae.

Article Snippet: Interventions, randomized treatment allocation, blinding and treatment The 3 mg ivermectin tablets (purchased from Merck and Co. Inc), 2 mg moxidectin tablets developed for human use, as well as placebo were provided by Wyeth in identical looking capsules.

Techniques:

Journal: PLoS Neglected Tropical Diseases

Article Title: A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca volvulus Infection

doi: 10.1371/journal.pntd.0002953

Figure Lengend Snippet: Percentage of participants with undetectable levels of skin microfilariae by treatment group and time post-treatment. A total e-mITT population, B Severely infected in the e-mITT population treated with ivermectin or 8 mg moxidectin.

Article Snippet: Interventions, randomized treatment allocation, blinding and treatment The 3 mg ivermectin tablets (purchased from Merck and Co. Inc), 2 mg moxidectin tablets developed for human use, as well as placebo were provided by Wyeth in identical looking capsules.

Techniques: Infection

Journal: Malaria Journal

Article Title: Filling gaps on ivermectin knowledge: effects on the survival and reproduction of Anopheles aquasalis, a Latin American malaria vector

doi: 10.1186/s12936-016-1540-y

Figure Lengend Snippet: Effects of ivermectin on the reproductive fitness of Anopheles aquasalis. a Effects on number of eggs per female (fecundity); b Effects on eggs that produced larvae (eggs hatch rate); c Effects on number of pupae that developed from larvae

Article Snippet: Future investigation concerning ivermectin effects on other important Amazonian species, such as Anopheles darlingi and Anopheles albitarsis , should be assessed prior to widespread adoption of ivermectin as a malaria elimination tool in the Amazon.

Techniques: Produced

Journal: Malaria Journal

Article Title: Filling gaps on ivermectin knowledge: effects on the survival and reproduction of Anopheles aquasalis, a Latin American malaria vector

doi: 10.1186/s12936-016-1540-y

Figure Lengend Snippet: Mortality proportion of mosquitoes fed with blood containing ivermectin at the second day after blood meals. Comparison of MFA and DFA methods (p

Article Snippet: Future investigation concerning ivermectin effects on other important Amazonian species, such as Anopheles darlingi and Anopheles albitarsis , should be assessed prior to widespread adoption of ivermectin as a malaria elimination tool in the Amazon.

Techniques: Direct Fluorescent Antibody Test

Journal: Malaria Journal

Article Title: Filling gaps on ivermectin knowledge: effects on the survival and reproduction of Anopheles aquasalis, a Latin American malaria vector

doi: 10.1186/s12936-016-1540-y

Figure Lengend Snippet: Effects of ivermectin on the survivorship of Anopheles aquasalis. a Mosquitoes fed on a volunteer blood meal with ivermectin 4 h post ingestion (HPI 4); b Mosquitoes fed on volunteers’ blood meal with ivermectin 2 days post ingestion (DPI 2); c Mosquitoes fed on volunteers’ blood meal with ivermectin 7 days post ingestion (DPI 7); d Mosquitoes fed on volunteers’ blood meal with ivermectin 14 days post ingestion (DPI 14)

Article Snippet: Future investigation concerning ivermectin effects on other important Amazonian species, such as Anopheles darlingi and Anopheles albitarsis , should be assessed prior to widespread adoption of ivermectin as a malaria elimination tool in the Amazon.

Techniques:

Journal: F1000Research

Article Title: Coronavirus disease 2019 drug discovery through molecular docking

doi: 10.12688/f1000research.24218.1

Figure Lengend Snippet: Reference molecules hydroxychloroquine, remdisivir, and ivermectin in complex with the COVID-19 main protease 6M03.

Article Snippet: Hydroxychloroquine is one such drug that is used worldwide whereas Remdesivir and Ivermectin have been reported to work against COVID-19in silico by others.

Techniques: